Let’s start with a brief overview of the company — how it started and some milestones. Mr. Fried: The company was started back in the Bronze Age, 25 years ago. It was started by its current founder ...

To start things off, I understand Vaxart is researching oral vaccines for COVID-19, norovirus, and influenza. Could you give us an overview of each program and where they are in the development ...

It’s been a few years since we last spoke. Can you give our readers a refresher on the company and its history? Dr. Bedu-Addo: So, PDS Biotechnology is developing immunotherapies that train the immune ...

So it’s been a few years since we last spoke. Let’s start with a brief overview and history of the company. Mr. Itescu: Sure. So Mesoblast has been publicly listed both on Nasdaq and the Australian ...

Tell us about the current trends and themes that are most impacting the space, the subsectors, you watch? Dr. Phipps: Sure. My coverage spans a range of biopharma companies, including large-caps such ...

We’ve spoken several times before, but can you just give our readers a brief refresher on the company and how it has evolved over the years? Mr. Do: BioVie is a biotech company that started developing ...

Recently you wrote a wonderful article that was published in Forbes magazine. In the context of an introduction to your coverage, what inspired you to write that piece, and what are some of the main ...

Complete Access to New Interviews, the Archive, and all Special Reports.

Interview with Ryan Zimmerman, Managing Director and Medical Technology Analyst, BTIG and former Director of Surgery at ...

In the context of an introduction to your coverage, how do you evaluate names in the medtech space? Mr. Zimmerman: The lens we look through is consistency of execution, whether internal expectations ...

We had the chance to interview you a couple years ago, and when we spoke in October 2023, your company was mainly focused on advancing the drug-eluting version of its CanGaroo bioenvelope. What is the ...

For readers who are not familiar with Butterfly Network, give us a short introduction. What problem are you solving, and why does ultrasound-on-chip matter clinically and economically? Mr. DeVivo: ...